AI-Powered CURAᵀᴹ Application for Identifying At-Risk Pregnancies in Obstetric Management
Launched by NATIONAL UNIVERSITY HOSPITAL, SINGAPORE · May 8, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "AI-Powered CURAᵀᴹ Application for Identifying At-Risk Pregnancies in Obstetric Management" is studying how using artificial intelligence (AI) can help doctors better identify which pregnancies are at higher risk. By improving the way pregnancies are screened, the goal is to ensure that women receive the right care early on, which could lead to better health outcomes for both mothers and their babies.
To participate in this study, women need to be between 21 and 50 years old and must be pregnant with only one baby. They should be no more than 13 weeks and 6 days along in their pregnancy at the time they join the trial. Participants will need to understand English since the AI tools being used are currently only available in that language. Although the trial is not yet recruiting participants, those who take part can expect to help improve pregnancy care by providing valuable information that may lead to better health strategies for at-risk pregnancies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age: 21 years old to 50 years old
- • Singleton Pregnancy
- • No more than 13 weeks' and 6 days' gestation at recruitment
- • Able to provide written, informed consent
- Exclusion Criteria:
- • Not proficient in the English language (AI intervention is only available in English at this stage)
About National University Hospital, Singapore
National University Hospital (NUH) in Singapore is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, NUH emphasizes a multidisciplinary approach, integrating cutting-edge medical research with high-quality patient care. The hospital collaborates with various stakeholders, including academic institutions and industry partners, to explore new therapies and improve treatment outcomes across a wide range of medical disciplines. Committed to ethical standards and patient safety, NUH plays a pivotal role in shaping the future of medicine in Singapore and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Sarah Li, MRCOG, MPH
Principal Investigator
National University Hospital, Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported